J&J Plays Down China Slowdown, Sees ’16 Bottom-Out
This article was originally published in PharmAsia News
Executive Summary
J&J's growth rate in China nearly halved compared to one year ago, but the world's largest pharma and medtech firm has used the time to tweak and improve its operations and is forecasting a better year ahead.